Gravity Analytica

Semler Scientific to Report Third Quarter and First Nine Months of 2024 Financial Results, Provide an Update on Bitcoin Holdings and Host Conference Call on November 4, 2024

SMLR 10.21.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-04

Name of Upcoming Event:Semler Scientific Call

Full Press Release SEC Filings Our SMLR Tweets

About Gravity Analytica

Recent Filings

SANTA CLARA, Calif.,Oct. 21, 2024/PRNewswire/ --Semler Scientific, Inc.(Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the third quarter and nine months endedSeptember 30, 2024, as well as provide an update on itsBitcoinholdings after the close ofU.S.financial markets onMonday, November 4, 2024.Doug Murphy-Chutorian, M.D., chief executive officer ofSemler Scientific, will host a conference call at4:30 pm ETthe same day.Eric Semler, chairman,Renae Cormier, chief financial officer, andJennifer Oliva-Herrington, chief operating officer, will join him on the call. Please submit questions prior to the start of the call toir@semlerscientific.com.

We encourage participants to pre-register for the conference call using the following link:https://dpregister.com/sreg/10193272/fda6de9798.Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Those without internet access or unable to pre-register may dial in by calling:Domestic callers: 833-816-1161International callers: 412-317-0717

Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived onSemler Scientific'swebsite atwww.semlerscientific.com.

About Semler Scientific, Inc.:Semler Scientific, Inc.develops, manufactures and markets innovative products and services to combat chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by theU.S. Food and Drug Administration(FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), andSemler Scientificis seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE).Semler Scientificalso invests inbitcoinand has adopted Bitcoinas its primary treasury asset. Additional information aboutSemler Scientificcan be found atwww.semlerscientific.com.

CONTACT:

Renae Cormier, CFOir@semlerscientific.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-report-third-quarter-and-first-nine-months-of-2024-financial-results-provide-an-update-on-bitcoin-holdings-and-host-conference-call-on-november-4-2024-302282117.html

SOURCESemler Scientific, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com